Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

257
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
257
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

659
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
659
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

319
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
319
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

472
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
472
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

141
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
141
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

The Implementation Imperative in Clinical Pharmacology.

Clinical pharmacology and therapeutics·2026
Same author

From Global Impact to Pharmacoequity: A Call to Action for Clinical Pharmacology.

Clinical pharmacology and therapeutics·2026
Same author

PBPK Modelling of PROTACs: Learnings from ARV-110 as a Case Example.

The AAPS journal·2026
Same author

PBPK Modelling of Antisense Oligonucleotide Therapeutics: Application for Predicting Plasma and Tissue Pharmacokinetics of Bepirovirsen.

The AAPS journal·2026
Same author

Tailoring Drug Therapy: Bridging Data Science and Clinical Reality.

Clinical pharmacology and therapeutics·2026
Same author

Evaluating the Impact of Intestinal Bile Salts on Drug Absorption Using PBPK Modeling: Case Studies With Efavirenz, Cinnarizine, and Posaconazole.

CPT: pharmacometrics & systems pharmacology·2026

Related Experiment Video

Updated: Jan 11, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.4K

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug-Drug Interaction

Kunal S Taskar1, Pradeep Sharma2, Karen Rowland Yeo3

  • 1Drug Metabolism and Pharmacokinetics, Research Technologies, GSK, Stevenage, UK.

Clinical Pharmacology and Therapeutics
|November 13, 2025
PubMed
Summary

Physiology Based Pharmacokinetic (PBPK) modeling aids drug-drug interaction (DDI) prediction. This perspective advocates practical sensitivity analysis (SA) approaches for PBPK-DDI evaluations to enhance clinical relevance.

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.5K
In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
05:47

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

14.5K

Related Experiment Videos

Last Updated: Jan 11, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.4K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.5K
In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
05:47

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox

Published on: August 28, 2019

14.5K

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Computational Biology and Bioinformatics

Background:

  • Physiology Based Pharmacokinetic (PBPK) modeling is crucial for predicting drug-drug interactions (DDIs).
  • Uncertainty in in vitro DDI parameters limits the accuracy of PBPK-DDI predictions.
  • Sensitivity analysis (SA) is commonly used to assess the impact of input parameters on PBPK-DDI predictions.

Purpose of the Study:

  • To explore and advocate practical approaches for sensitivity analysis (SA) in precipitant (inhibitor/inducer) Physiology Based Pharmacokinetic (PBPK) drug-drug interaction (DDI) studies.
  • To enhance the clinical relevance and reliability of PBPK-DDI evaluations through optimized SA strategies.

Main Methods:

  • The study reviews and discusses existing methodologies for conducting sensitivity analysis (SA) within the context of PBPK-DDI modeling.
  • It focuses on practical approaches for analyzing the impact of precipitant drug parameters (inhibitors/inducers) on PBPK-DDI predictions.
  • The perspective emphasizes the integration of SA for robust clinical DDI assessment and study design.

Main Results:

  • Sensitivity analysis (SA) is essential for understanding the influence of input parameter uncertainty on PBPK-DDI predictions.
  • Practical SA approaches can help prioritize which parameters require more accurate in vitro determination.
  • Optimized SA can improve the clinical relevance of PBPK-DDI predictions, aiding in study design and prioritization.

Conclusions:

  • Implementing practical sensitivity analysis (SA) is vital for overcoming limitations associated with parameter uncertainty in Physiology Based Pharmacokinetic (PBPK) drug-drug interaction (DDI) modeling.
  • Advocating for specific SA approaches can lead to more reliable and clinically relevant PBPK-DDI evaluations.
  • This perspective provides a framework for optimizing SA in PBPK-DDI studies, ultimately improving drug development and patient safety.